Pictet Asset Management (UK)’s Travere Therapeutics TVTX Stock Holding History

Pictet Asset Management (UK)’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$5.14M	Buy	352,423 +222,262	+171%	+$4.38M	0.01%	845
2021 Q1	$3.25M	Buy	+130,161	New	+$3.6M	﹤0.01%	920
2019 Q4	–	Sell	-70,288	Closed	-$815K	–	1141
2019 Q3	$815K	Buy	70,288 +8,492	+14%	+$140K	﹤0.01%	935
2019 Q2	$1.24M	Buy	+61,796	New	+$1.22M	﹤0.01%	905

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Pictet Asset Management (UK)'s TVTX Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its Travere Therapeutics (TVTX) stake by 171% in Q2 2021, buying an estimated $4.38M and bringing the position to 352,423 shares worth $5.14M. The position accounts for 0.01% of the portfolio, ranked #845.

Pictet Asset Management (UK) first reported a position in TVTX in Q2 2019 and has held it in 4 quarters since. 136 funds tracked by Wall St. Rank hold TVTX as of Q2 2021.

Pictet Asset Management (UK) held 352,423 shares of Travere Therapeutics worth $5.14M as of Q2 2021.
Pictet Asset Management (UK) bought 222,262 Travere Therapeutics shares in Q2 2021, an estimated $4.38M.
Travere Therapeutics made up 0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #845 holding.
Pictet Asset Management (UK) first reported a position in Travere Therapeutics in Q2 2019 and has held it in 4 quarters since.
136 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.